Literature DB >> 7505939

Oral absorption of FK506 in rats.

A Kagayama1, S Tanimoto, J Fujisaki, A Kaibara, K Ohara, K Iwasaki, Y Hirano, T Hata.   

Abstract

The oral absorption of FK506 in solid dispersion formulation was studied in rats. The obtained area under the concentration versus time curve (AUC) increased in a nonlinear fashion with a small dose-dependent increase in the peak blood concentrations (Cmax). The peak concentration time (Tmax) was observed within 30 min after administration in all dosing groups (1-10 mg/kg) with or without feeding, whereas the oral absorption of FK506 was reduced to about 50% by gavage at a dose of 1 mg/kg. Participation of first-pass elimination was suggested by comparing the blood levels after infusion via the portal vein with those after infusion via the femoral vein. Further, in an in vitro stability study and an in situ loop absorption study, FK506 was fairly stable in the gastrointestinal juice and was absorbed predominantly from the upper part of the small intestine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505939     DOI: 10.1023/a:1018967107612

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  Pharmacokinetics of FK 506: preclinical and clinical studies.

Authors:  R Venkataramanan; A Jain; E Cadoff; V Warty; K Iwasaki; K Nagase; A Krajack; O Imventarza; S Todo; J J Fung
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitamin E.

Authors:  R J Sokol; K E Johnson; F M Karrer; M R Narkewicz; D Smith; I Kam
Journal:  Lancet       Date:  1991-07-27       Impact factor: 79.321

3.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

4.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

Authors:  T Kino; H Hatanaka; M Hashimoto; M Nishiyama; T Goto; M Okuhara; M Kohsaka; H Aoki; H Imanaka
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

5.  Biopharmaceutical aspects of FK-506.

Authors:  R Venkataramanan; V S Warty; M A Zemaitis; A T Sanghvi; G J Burckart; H Seltman; S Todo; L Makowka; T E Starzl
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

6.  A highly sensitive method to assay FK-506 levels in plasma.

Authors:  K Tamura; M Kobayashi; K Hashimoto; K Kojima; K Nagase; K Iwasaki; T Kaizu; H Tanaka; M Niwa
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

7.  Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size.

Authors:  B D Tarr; S H Yalkowsky
Journal:  Pharm Res       Date:  1989-01       Impact factor: 4.200

Review 8.  The effects of food on drug bioavailability.

Authors:  P A Winstanley; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

9.  Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats.

Authors:  K Takada; H Usuda; M Oh-Hashi; H Yoshikawa; S Muranishi; H Tanaka
Journal:  J Pharmacobiodyn       Date:  1991-01

10.  The absorption site of cyclosporin in the human gastrointestinal tract.

Authors:  J Drewe; C Beglinger; T Kissel
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

View more
  6 in total

1.  FK506 microparticles mitigate experimental colitis with minor renal calcineurin suppression.

Authors:  Alf Lamprecht; Hiromitsu Yamamoto; Nathalie Ubrich; Hirofumi Takeuchi; Philippe Maincent; Yoshiaki Kawashima
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

2.  Novel gastroretentive sustained-release tablet of tacrolimus based on self-microemulsifying mixture: in vitro evaluation and in vivo bioavailability test.

Authors:  Yan-ping Wang; Yong Gan; Xin-xin Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-09-19       Impact factor: 6.150

3.  Pharmacokinetic advantages of a newly developed tacrolimus oil-in-water-type emulsion via the enteral route.

Authors:  T Uno; T Kazui; Y Suzuki; H Hashimoto; K Suzuki; B A Muhammad
Journal:  Lipids       Date:  1999-03       Impact factor: 1.880

4.  Effect of Jejunal Administration on Tacrolimus Trough Concentrations in a Pediatric Liver Transplant Recipient.

Authors:  Alexandra Aldieri; Esther Bae; Mary Moss Chandran
Journal:  J Pediatr Pharmacol Ther       Date:  2022-05-09

5.  Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing.

Authors:  Kirk A Overhoff; Jason T McConville; Wei Yang; Keith P Johnston; Jay I Peters; Robert O Williams
Journal:  Pharm Res       Date:  2007-10-30       Impact factor: 4.200

6.  Orally Disintegrating Tablets Containing Melt Extruded Amorphous Solid Dispersion of Tacrolimus for Dissolution Enhancement.

Authors:  Poovizhi Ponnammal; Parijat Kanaujia; Yin Yani; Wai Kiong Ng; Reginald B H Tan
Journal:  Pharmaceutics       Date:  2018-03-16       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.